Seat­tle-based Covid-19 vac­cine de­vel­op­er seeks $950M from In­di­an part­ner over trade se­cret theft

Seat­tle-based HDT Bio, which is de­vel­op­ing an saR­NA vac­cine to pre­vent Covid-19, on Mon­day sued In­dia-based Em­cure for $950 mil­lion, say­ing that Em­cure sought to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER